The Anti-Proliferative Effect of 5-Fluorouracil on Tumor Is Highly Associated with the Renewal of Peripheral White Blood Cells


The efficacy of chemotherapy is thought to be direct killing of tumor cells, but documented studies have been shown that immunity plays a role in its effectiveness. In a pilot study to observe the bone marrow suppression and regeneration in tumor bearing mice induced by single dose injection of 5-fluorouracil (5-FU), we unexpectedly found that tumors grew fast as bone marrow mononuclear cells (BMC) and peripheral white blood cells (PWBC) were decreased quickly during myelosuppression meanwhile significantly slow as repopulating of BMC and PWBC during bone marrow regeneration after 5-FU treatment, no matter whether in low or high dose administration, but the higher the dose was, the lower of the nadir of BMC and PWBC were reached to, as well as the much more powerful duration and strength of the repopulated BMC and PWBC, suggested that the immunity might be a predominant drive in 5-FU chemotherapy. Due to the fact that BMC is the source of PWBC which is its final maturational and functional form, it could be proposed that the anti-proliferative effect of 5-FU on tumor is highly associated with the renewal of PWBC.

Share and Cite:

Qian, X. , Qian, X. , Chen, X. , Ge, M. , Chen, D. and Mao, W. (2015) The Anti-Proliferative Effect of 5-Fluorouracil on Tumor Is Highly Associated with the Renewal of Peripheral White Blood Cells. Journal of Cancer Therapy, 6, 594-600. doi: 10.4236/jct.2015.67064.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Harrison, D.E. and Lerner, C.P. (1991) Most Primitive Hematopoietic Stem Cells Are Stimulated to Cycle Rapidly after Treatment with 5-Fluorouracil. Blood, 78, 1237-1240.
[2] Dudley, M.E., Wunderlich, J.R., Robbins, P.F., Yang, J.C., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Sherry, R., Restifo, N.P., Hubicki, A.M., Robinson, M.R., Raffeld, M., Duray, P., Seipp, C.A., Rogers-Freezer, L., Morton, K.E., Mavroukakis, S.A., White, D.E. and Rosenberg, S.A. (2002) Cancer Regression and Autoimmunity in Patients after Clonal Repopulation with Antitumor Lymphocytes. Science, 298, 850-854.
[3] Shurin, G.V., Tourkova, I.L., Kaneno, R. and Shurin, M.R. (2009) Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism. The Journal of Immunology, 183, 137-144.
[4] Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C. and Ghiringhelli, F. (2010) 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity. Cancer Research, 70, 3052-3061.
[5] Kaneno, R., Shurin, G.V., Kaneno, F.M., Naiditch, H., Luo, J. and Shurin, M.R. (2011) Chemotherapeutic Agents in Low Noncytotoxic Concentrations Increase Immunogenicity of Human Colon Cancer Cells. Cellular Oncology (Dordrecht), 34, 97-106.
[6] McCoy, M.J., Lake, R.A., van der Most, R.G., Dick, I.M. and Nowak, A.K. (2012) Post-Chemotherapy T-Cell Recovery Is a Marker of Improved Survival in Patients with Advanced Thoracic Malignancies. British Journal of Cancer, 107, 1107-1115.
[7] Zhang, L., Feng, D., Yu, L.X., Tsung, K. and Norton, J.A. (2013) Preexisting Antitumor Immunity Augments the Antitumor Effects of Chemotherapy. Cancer Immunology, Immunotherapy, 62, 1061-1071.
[8] Rambaldi, A., Borleri, G., Dotti, G., Bellavita, P., Amaru, R., Biondi, A. and Barbui, T. (1998) Innovative Two-Step Negative Selection of Granulocyte Colony-Stimulating Factor-Mobilized Circulating Progenitor Cells: Adequacy for Autologous and Allogeneic Transplantation. Blood, 91, 2189-2196.
[9] Mellman, I., Coukos, G. and Dranoff, G. (2011) Cancer Immunotherapy Comes of Age. Nature, 480, 480-489.
[10] Ghiringhelli, F., Menard, C., Puig, P.E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L. and Chauffert, B. (2007) Metronomic Cyclophosphamide Regimen Selectively Depletes CD4+CD25+ Regulatory T Cells and Restores T and NK Effector Functions in End Stage Cancer Patients. Cancer Immunology, Immunotherapy, 56, 641-648.
[11] Motoyoshi, Y., Kaminoda, K., Saitoh, O., Hamasaki, K., Nakao, K., Ishii, N., Nagayama, Y. and Eguchi, K. (2006) Different Mechanisms for Anti-Tumor Effects of Low- and High-Dose Cyclophosphamide. Oncology Reports, 16, 141-146.
[12] Shevchenko, I., Karakhanova, S., Soltek, S., Link, J., Bayry, J., Werner, J., Umansky, V. and Bazhin, A.V. (2013) Low-Dose Gemcitabine Depletes Regulatory T Cells and Improves Survival in the Orthotopic Panc02 Model of Pancreatic Cancer. International Journal of Cancer, 133, 98-107.
[13] Sevko, A., Michels, T., Vrohlings, M., Umansky, L., Beckhove, P., Kato, M., Shurin, G.V., Shurin, M.R. and Umansky, V. (2013) Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model. The Journal of Immunology, 190, 2464-2471.
[14] Wada, S., Yoshimura, K., Hipkiss, E.L., Harris, T.J., Yen, H.R., Goldberg, M.V., Grosso, J.F., Getnet, D., Demarzo, A.M., Netto, G.J., Anders, R., Pardoll, D.M. and Drake, C.G. (2009) Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model. Cancer Research, 69, 4309-4318.
[15] Le, H.K., Graham, L., Cha, E., Morales, J.K., Manjili, M.H. and Bear, H.D. (2009) Gemcitabine Directly Inhibits Myeloid Derived Suppressor Cells in BALB/c Mice Bearing 4T1 Mammary Carcinoma and Augments Expansion of T Cells from Tumor-Bearing Mice. International Immunopharmacology, 9, 900-909.
[16] Tongu, M., Harashima, N., Monma, H., Inao, T., Yamada, T., Kawauchi, H. and Harada, M. (2013) Metronomic Chemotherapy with Low-Dose Cyclophosphamide plus Gemcitabine Can Induce Anti-Tumor T Cell Immunity in Vivo. Cancer Immunology, Immunotherapy, 62, 383-391.
[17] Rozados, V.R., Mainetti, L.E., Rico, M.J., Zacarías Fluck, M.F., Matar, P. and Scharovsky, O.G. (2010) The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy with Cyclophosphamide. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 18, 601-605.
[18] Le, D.T. and Jaffee, E.M. (2012) Regulatory T-Cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective. Cancer Research, 72, 3439-3444.
[19] Tschmelitsch, J., Barendswaard, E., Williams Jr., C., Yao, T.J., Cohen, A.M., Old, L.J. and Welt, S. (1997) Enhanced Antitumor Activity of Combination Radioimmunotherapy (131I-Labeled Monoclonal Antibody A33) with Chemotherapy (Fluorouracil). Cancer Research, 57, 2181-2186.
[20] Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leigh, N., Mezger, J., Archer, V., Moore, N. and Manegold, C. (2009) Phase III Trial of Cisplatin Plus Gemcitabine with Either Placebo or Bevacizumab as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL. Journal of Clinical Oncology, 27, 1227-1234.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.